Metopirone (Metyrapone)

Metyrapone blocks the enzyme 11‑beta‑hydroxylase (CYP11B1) in the adrenal cortex, preventing the final step of cortisol synthesis. This reduces cortisol levels, triggers a rise in ACTH, and increases adrenal androgen output, which can be measured for diagnostic purposes.

The specific dose of Metopirone is determined by the prescribing physician based on the individual patient's condition, severity, and response to therapy. Dosage regimens are not standardized and should follow the prescriber's instructions.

The safety of Metopirone in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant.

To order Metopirone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metopirone (metyrapone) differs from other inhibitors such as ketoconazole or osilodrostat in its specific target of 11‑beta‑hydroxylase. It is often preferred for diagnostic testing because its effect is reversible and it provides a clear biochemical profile, whereas other agents may have broader enzyme inhibition and distinct side‑effect profiles.

Metopirone tablets should be stored at room temperature, below 25 °C, in their original packaging. Protect them from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

Metopirone is taken orally as a tablet. The exact timing and frequency are prescribed by the treating physician, often with meals or as directed to optimize absorption and minimize gastrointestinal discomfort.

The most serious risks include adrenal insufficiency, which can cause severe fatigue, hypotension, and electrolyte disturbances, and severe hypertension. Prompt medical attention is required if these symptoms develop while on therapy.

Metopirone should be avoided in individuals with known hypersensitivity to metyrapone or any tablet excipients, and in patients where cortisol reduction could be dangerous, such as those with uncontrolled cardiovascular disease or active adrenal insufficiency.